Althea Technologies, Inc. (San Diego, CA, www.altheatech.com), has been contracted by GeoVax Labs, Inc. (Atlanta, GA, www.geovax.com), to manufacturer its HIV-1 DNA vaccine.
Althea Technologies, Inc. (San Diego, CA, www.altheatech.com), has been contracted by GeoVax Labs, Inc. (Atlanta, GA, www.geovax.com), to manufacturer its HIV-1 DNA vaccine. This vaccine will be used in GeoVax’s advanced Phase 2 human trials planned to start in early 2008. GeoVax AIDS vaccines are designed to prevent development of Acquired Immunodeficiency Disease (AIDS) caused by the virus known as HIV-1, by vaccinating individuals before their infection with the AIDS virus. The GeoVax vaccine regimen employs a “prime-boost strategy.” Trial participants are administered the GeoVax HIV-1 DNA vaccine, which “primes” the immune system, followed by the GeoVax HIV-1 MVA (Modified Vaccinia Virus) boost.
